Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Impact of the microbiota GvHD and post-transplant survival outcomes

Florent Malard • 6 Dec 2021
ASH 2021
General

Florent Malard, MD, PhD, Saint Antoine Hospital, Paris, France, provides updates on the role of the microbiota in graft versus host disease (GvHD) pathophysiology. Dr Malard highlights the contribution of fungi and viruses in transplant survival rates; presence of the fungus Candida albicans is associated with inferior survival rates in patients undergoing transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Florent Malard

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:04
Retrospective study on the outcomes of patients with myeloma treated with cilta-cel and ide-cel
Florent Malard • 20 May 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals